Skip to main content

GSK · GSK plc · Documents

Track GSK — free
$48.58 -0.66 (-1.34%) At close · Nov 18 Q3 2026 earnings call transcript
Market Cap
$97.38B
Shares
2.00B
Volume · Nov 18 2.2M Avg daily vol (3M) 4.03M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue 32.67B GBP up 4.1% 20-F filed Mar 6, 2026 Earnings call Q3 2026 earnings call Held Oct 28, 2026
2026
Nov 18
Current report 6-K
FDA grants accelerated approval to Nelkarmi for ALK-positive lung cancer

GSK said the FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated advanced ALK-positive non-small cell lung cancer. In the trial, the confirmed overall response rate was 49% (33/67) in patients previously treated with alectinib only.

2 source passages
the US Food and Drug Administration (FDA) has granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received For patients previously treated with alectinib as their only prior ALK TKI, the confirmed overall response rate (ORR) was 49% (33/67; 95% CI: 37%, 62%) Open the document at this passage
Nov 17
Investor event
Restructuring to deliver 1.9 billion of costs by 29

GSK plans to deliver 1.9 billion of costs by 29 through restructuring across its value chain, with most of the savings reinvested in R&D. It also says it will not slow down on BD.

3 source passages
Part of that is taking out or delivering 1.9 billion of costs by 29. Most of that will be reinvested in R&D. And of course, on top of all of that, we're not going to slow down on BD. Open the document at this passage
Nov 17
Current report 6-K
Directors and executives acquire ADS via dividend reinvestment at $50.4500

GSK plc reports that Hal Barron, James Ford and Maya Martinez-Davis acquired American Depositary Shares via dividend reinvestment in executive savings plan accounts on 2026-11-13 at $50.4500.

5 source passages
Acquisition of notional ADS within Dr Barron’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends Acquisition of notional ADS within Mr Ford’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends $50.4500 2026-11-13 Open the document at this passage
Nov 13
Current report 6-K
CHMP supports one-dose Bexsero booster for ages 10+

GSK plc announced CHMP recommended updating the Bexsero label for a single booster dose in individuals aged 10 years and older vaccinated at least two years earlier. Men-B-096 met its primary endpoint, showing immune memory from infant vaccination can be boosted up to 19 years later.

5 source passages
Bexsero (4CMenB) receives positive CHMP opinion for one-dose Meningitis B booster for 10+ year olds GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended updating the Bexsero label to include a single booster dose for individuals aged 10 years and older who were previously vaccinated at least two years earlier with Bexsero. The recommendation is supported by data showing that immune memory established following primary vaccination in infancy can be boosted with a single dose up to 19 years later1. The CHMP’s positive opinion is based on data from Men-B-096, a Phase IIIb open label, multi-centre study which assessed the immune response and safety of a single booster dose of Bexsero in healthy individuals aged 10-20 years who previously completed their primary vaccination series with Bexsero. The study met its primary endpoint. Open the document at this passage
Nov 12
Current report 6-K
Executives and PCA acquired shares under reward plans

GSK plc disclosed that Lynn Baxter and other executives or a PCA acquired ordinary shares under the Share Reward Plan at £19.3453 on 2026-11-10. Maya Martinez-Davis acquired 9.264 notional ADS at $51.5400 on 2026-11-09.

9 source passages
Lynn Baxter Acquisition of Ordinary Shares under the Company’s Share Reward Plan £19.3453 2026-11-10 Maya Martinez-Davis Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account $51.5400 9.264 2026-11-09 Open the document at this passage
Nov 10
Investor event
Long-acting TSLP pivotal phase three starts accelerated by nine months

GSK accelerated six pivotal phase three starts for its long-acting TSLP, Falcora Kibart, across asthma, nasal polyps and COPD, a very material acceleration of nine months. Management said there is absolutely no uncertainty that the drug is a twice yearly dose medicine, and the data will be shared next year.

6 source passages
So, our long-acting TSLP, Falcora Kibart, it's called now. we were able to accelerate six pivotal phase three starts, again, in conjunction with the data we had from nasal polyps. And that provided a very material acceleration of nine months. And that's the persist program across, as you say, asthma, nasal polyps, and COPD. What I can tell you now is that there's absolutely no uncertainty that it's a twice yearly dose medicine. We're going to share the data next year. Open the document at this passage
Nov 6
Current report 6-K
Provisional 2027 dividend schedule announced

GSK plc announced provisional dividend dates for 2027, including Q1 results on Wednesday 28 April 2027 and payment on Thursday 15 July 2027, and Q4 results on Wednesday 2 February 2028 and payment on Thursday 13 April 2028.

4 source passages
GSK plc GSK publishes provisional dividend dates Q1 2027 | Wednesday 28 April 2027 | Thursday 13 May 2027 | Friday 14 May 2027 | Friday 14 May 2027 | Thursday 24 June 2027 | Thursday 15 July 2027 Q4 2027 | Wednesday 2 February 2028 | Friday 18 February 2028 | Friday 18 February 2028 | Friday 18 February 2028 | Thursday 23 March 2028 | Thursday 13 April 2028 Open the document at this passage
Nov 2
Current report 6-K
Total voting rights total 4,045,439,182

GSK plc reported 4,045,439,182 total voting rights as at 31 October 2026, based on 4,316,320,246 issued ordinary shares and 270,881,064 treasury shares.

2 source passages
GSK plc (the ‘Company’) hereby notifies the market of the following: The Company’s issued share capital as at 31 October 2026 consisted of 4,316,320,246 shares of 31 ¼ pence each (‘Ordinary Shares’), of which 270,881,064 Ordinary Shares were held in Treasury. Therefore, the total number of voting rights in the Company is 4,045,439,182. Open the document at this passage
Oct 28
Earnings call
Sales rise 5% to £8.9 billion; 2026 guidance reconfirmed

GSK reported sales up 5% to £8.9 billion and core operating profit up 5%, with core earnings per share up 1%. It reconfirmed 2026 guidance, with sales expected in the upper half of the range. Charges under the Accelerate Growth programme are now expected to be up to £1bn in 2026.

Read from the first part of this long document
5 source passages
we have continued operational momentum with sales up 5% to £8.9 billion pounds. Core operating profit grew 5% and core earnings per share were up 1%. Given our operating momentum and launch progress we are pleased to reconfirm 2026 guidance today. Sales are expected in the upper half of the range, driven by Specialty performance. And we now expect charges of up to £1bn in 2026. Open the document at this passage
Oct 28
Current report 6-K
Q3 sales rise 5% at CER, core profit grows 5%

GSK reported Q3 sales of £8.9 billion, up 5% at CER, with core operating profit up 5%. It reaffirmed 2026 guidance for turnover growth of 3% to 5% and core operating profit growth of 7% to 9%.

Read from the first part of this long document
5 source passages
Total Q3 sales £8.9 billion +4% AER; +5% CER Core operating profit +5% and Core EPS +1% reflecting higher sales, favourable product and regional mix and higher royalty income, partly offset by increased investment in R&D and new asset launches and higher finance costs GSK reaffirms its full-year 2026 guidance at constant exchange rates (CER). Turnover is expected to increase between 3% to 5%, at the upper half of the range Core operating profit is expected to increase between 7% to 9%, at the upper half of the range Open the document at this passage
Oct 26
Current report 6-K
Current report

GSK’s ARTEMIS-011 trial found Ris-Rez reduced disease progression or death risk by 67% versus chemotherapy in relapsed osteosarcoma, with median progression-free survival of 5.5 months versus 1.4 months; Hansoh plans a China regulatory submission.

Oct 26
Current report 6-K
Current report

GSK plc reported that Maya Martinez-Davis acquired notional American Depositary Shares in her GSK Executive Supplemental Savings Plan account on 2026-10-22, at $51.2100 for volume 9.324, on the New York Stock Exchange (XNYS).

Oct 26
Current report 6-K
Current report

GSK plc reported interim AZUR-1 results: 76% of evaluable patients achieved complete response to Jemperli monotherapy; independent review showed 47% achieved sustained cCR12, with no recurrences among responders after median follow-up of more than two years.

Oct 26
Current report 6-K
Current report

GSK reported positive phase Ib BEHOLD-1 results for Mo-Rez in platinum-resistant ovarian cancer: 62% confirmed objective response rate, 12.2-month median duration of response and 11.1-month median progression-free survival; five pivotal phase III studies are underway.

Oct 21
Current report 6-K
Current report

GSK plc announced that the FDA approved Hibsago (bepirovirsen) for certain adults with chronic hepatitis B, with phase III trials showing a 19% functional cure rate after six-month treatment versus less than 1% for standard care alone.

Oct 19
Current report 6-K
Current report

GSK announced the US FDA approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer under the accelerated approval pathway. Approval was based on phase II AZUR-1 trial data.

Oct 19
Current report 6-K
Current report

GSK presented first global data for its B7-H3-targeted ADC Ris-Rez in relapsed extensive-stage small cell lung cancer, showing a 61% confirmed ORR at 8 mg/kg (n=11/18; 95% CI: 35.7-82.7) versus 32% at 6 mg/kg, supporting its global phase III EMBOLD SCLC-301 study.

Oct 15
Current report 6-K
Current report

On 2026-10-13, GSK plc executives James Ford, Maya Martinez-Davis and Shobie Ramakrishnan acquired American Depositary Shares through dividend reinvestment, purchasing 326.441, 351.842 and 724.875 shares respectively at $46.9482 each on the New York Stock Exchange (XNYS).

Oct 14
Current report 6-K
Current report

GSK plc reported increases in executives’ notional interests from dividend reinvestment on 2026-10-12, involving Ordinary Shares and American Depositary Shares.

Oct 13
Current report 6-K
Current report

GSK plc reported dividend-reinvestment acquisitions by executives and directors, including ordinary shares at £17.5904 on 2026-10-08 and American Depositary Shares at $46.5883 on 2026-10-09.

Oct 13
Current report 6-K
Current report

GSK plc reported PDMR and closely associated person acquisitions through dividend reinvestment and Share Reward Plan awards, plus a notional ADS purchase, on 2026-10-07, 2026-10-08 and 2026-10-09.

Oct 8
Current report 6-K
Current report

GSK plc announced that Wendy Becker, an independent Non-Executive Director, was appointed as a Non-Executive Director of Tesco PLC effective 1 November 2026.

Oct 6
Current report 6-K
Current report

GSK plc notified that 19,352 ordinary shares of 31¼ pence each were admitted to the London Stock Exchange – Main Market, bringing the total to 4,316,311,662 for 7 August 2026 – 2 October 2026.

Oct 1
Current report 6-K
Current report

GSK plc reported 4,045,430,485 total voting rights as at 30 September 2026, based on 4,316,311,549 issued Ordinary Shares, of which 270,881,064 were held in Treasury.

Sep 24
Current report 6-K
Current report

GSK plc disclosed that Maya Martinez-Davis acquired 9.414 notional American Depositary Shares on 2026-09-22, at $50.7200 per ADS, through her Executive Supplemental Savings Plan on the New York Stock Exchange.

Sep 22
Current report 6-K
Current report

GSK plc disclosed director purchases of Ordinary Shares and ADS on 2026-09-18.

Showing 1–50 of 1,359 documents
Key facts CIK 1131399 CUSIP 37733W204 13F (30d) 922 filings 845 filers Visit website Investor relations